[Clinical Functionality of Dispersive OVDs: Improvement of One of the Properties of 3% Hyaluronic Acid and 4% Chondroitin Sulfate Combination].

MLA

Watanabe, Ippei, et al. “[Clinical Functionality of Dispersive OVDs: Improvement of One of the Properties of 3% Hyaluronic Acid and 4% Chondroitin Sulfate Combination].” Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, vol. 142, no. 4, 2022, pp. 401–11. EBSCOhost, https://doi.org/10.1248/yakushi.21-00208.

APA

Watanabe, I., Suzuki, K., Nagata, M., & Matsushima, H. (2022). [Clinical Functionality of Dispersive OVDs: Improvement of One of the Properties of 3% Hyaluronic Acid and 4% Chondroitin Sulfate Combination]. Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, 142(4), 401–411. https://doi.org/10.1248/yakushi.21-00208

Chicago

Watanabe, Ippei, Kiyoshi Suzuki, Mayumi Nagata, and Hiroyuki Matsushima. 2022. “[Clinical Functionality of Dispersive OVDs: Improvement of One of the Properties of 3% Hyaluronic Acid and 4% Chondroitin Sulfate Combination].” Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan 142 (4): 401–11. doi:10.1248/yakushi.21-00208.